vs
Side-by-side financial comparison of PERRIGO Co plc (PRGO) and WEIBO Corp (WB). Click either name above to swap in a different company.
WEIBO Corp is the larger business by last-quarter revenue ($1.3B vs $1.1B, roughly 1.2× PERRIGO Co plc). WEIBO Corp runs the higher net margin — 35.7% vs -127.8%, a 163.5% gap on every dollar of revenue. Over the past eight quarters, WEIBO Corp's revenue compounded faster (22.6% CAGR vs 1.3%).
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
Weibo Corporation is a Chinese social network company known for the microblogging website Sina Weibo. It is based in Beijing, China.
PRGO vs WB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.3B |
| Net Profit | $-1.4B | $458.3M |
| Gross Margin | 32.6% | — |
| Operating Margin | -116.0% | 29.1% |
| Net Margin | -127.8% | 35.7% |
| Revenue YoY | -2.5% | — |
| Net Profit YoY | -3093.9% | — |
| EPS (diluted) | $-10.23 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.1B | $841.7M | ||
| Q1 25 | $1.0B | $396.9M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | $1.3B | ||
| Q2 24 | $1.1B | $833.4M | ||
| Q1 24 | $1.1B | $395.5M |
| Q4 25 | $-1.4B | — | ||
| Q3 25 | $7.5M | $458.3M | ||
| Q2 25 | $-8.4M | $234.8M | ||
| Q1 25 | $-6.4M | $108.1M | ||
| Q4 24 | $-44.4M | — | ||
| Q3 24 | $-21.0M | $297.4M | ||
| Q2 24 | $-108.4M | $164.6M | ||
| Q1 24 | $2.0M | $51.1M |
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — | ||
| Q1 24 | 33.1% | — |
| Q4 25 | -116.0% | — | ||
| Q3 25 | 7.0% | 29.1% | ||
| Q2 25 | 4.3% | 30.4% | ||
| Q1 25 | 4.5% | 27.8% | ||
| Q4 24 | 10.0% | — | ||
| Q3 24 | 7.4% | 29.0% | ||
| Q2 24 | -2.5% | 28.2% | ||
| Q1 24 | -5.1% | 25.2% |
| Q4 25 | -127.8% | — | ||
| Q3 25 | 0.7% | 35.7% | ||
| Q2 25 | -0.8% | 27.9% | ||
| Q1 25 | -0.6% | 27.2% | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | -1.9% | 22.9% | ||
| Q2 24 | -10.2% | 19.8% | ||
| Q1 24 | 0.2% | 12.9% |
| Q4 25 | $-10.23 | — | ||
| Q3 25 | $0.05 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $-0.32 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.79 | — | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.9B | $3.9B |
| Total Assets | $8.5B | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $432.1M | $1.1B | ||
| Q2 25 | $454.2M | $1.2B | ||
| Q1 25 | $409.9M | $1.2B | ||
| Q4 24 | $558.8M | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $542.8M | $1.9B | ||
| Q1 24 | $658.5M | $2.1B |
| Q4 25 | $2.9B | — | ||
| Q3 25 | $4.4B | $3.9B | ||
| Q2 25 | $4.5B | $3.6B | ||
| Q1 25 | $4.4B | $3.5B | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.5B | $3.4B | ||
| Q1 24 | $4.7B | $3.3B |
| Q4 25 | $8.5B | — | ||
| Q3 25 | $10.1B | $6.9B | ||
| Q2 25 | $10.1B | $6.5B | ||
| Q1 25 | $9.8B | $6.7B | ||
| Q4 24 | $9.6B | — | ||
| Q3 24 | $11.2B | — | ||
| Q2 24 | $10.4B | $7.1B | ||
| Q1 24 | $10.6B | $7.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.4M | — |
| Free Cash FlowOCF − Capex | $148.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $145.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.4M | — | ||
| Q3 25 | $51.7M | — | ||
| Q2 25 | $75.9M | — | ||
| Q1 25 | $-64.5M | — | ||
| Q4 24 | $312.6M | — | ||
| Q3 24 | $42.2M | — | ||
| Q2 24 | $9.5M | — | ||
| Q1 24 | $-1.4M | — |
| Q4 25 | $148.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | — | ||
| Q1 25 | $-90.0M | — | ||
| Q4 24 | $274.9M | — | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $-18.9M | — | ||
| Q1 24 | $-26.5M | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | -1.8% | — | ||
| Q1 24 | -2.4% | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
